Chronology of COVID-19 Cases on the Diamond Princess Cruise Ship and Ethical Considerations: A Report From Japan.


Journal

Disaster medicine and public health preparedness
ISSN: 1938-744X
Titre abrégé: Disaster Med Public Health Prep
Pays: United States
ID NLM: 101297401

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 25 3 2020
medline: 1 1 2021
entrez: 25 3 2020
Statut: ppublish

Résumé

The Diamond Princess cruise ship has been anchored at the Yokohama port in Japan since February 3, 2020. A total of 691 cases of the coronavirus disease 2019 (COVID-19) infection had been confirmed as of February 23. The government initially assumed that the infection was not spreading aboard and therefore indicated that any persons who either tested negative for the virus or were asymptomatic should immediately disembark. However, on February 5, the government set a 14-day health observation period because of the severity of the infection. Passengers confirmed to be free from infection began disembarking on Day 15 (February 19) of the quarantine. The effectiveness and validity of infection control, justification for the timing of inspections, and even the nature of COVID-19 itself now are all in question. The ethical considerations related to cruise ship infection control include the reasonable justification for isolation, the psychological fragility and quality of life of the isolated passengers and crew members, the procedural justice inherent in a forced quarantine, and the optimization of control measures.The international coordination framework and the global ramifications of such outbreaks should be reevaluated by the international community. Denying a ship's entry based on local politics is incompatible with global justice. Events such as these require an international response and global regulations that seek to reduce disparities.

Identifiants

pubmed: 32207674
pii: S1935789320000506
doi: 10.1017/dmp.2020.50
pmc: PMC7156812
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

506-513

Références

Camb Q Healthc Ethics. 2012 Jul;21(3):392-5
pubmed: 22624543

Auteurs

Eisuke Nakazawa (E)

Department of Biomedical Ethics, School of Public Health, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.

Hiroyasu Ino (H)

Tokyo Metropolitan Geriatrics Hospital, Tokyo, Japan.

Akira Akabayashi (A)

Department of Biomedical Ethics, School of Public Health, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Division of Medical Ethics, Department of Population Health, New York University School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH